Claraphi Advisory Network’s TherapeuticsMD TXMD Stock Holding History

Claraphi Advisory Network’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-510	Closed	-$167K	–	270
2018 Q3	$167K	Hold	510	–	–	0.09%	243
2018 Q2	$159K	Sell	510 -200	-28%	-$61.1K	0.1%	253
2018 Q1	$173K	Sell	710 -200	-22%	-$56.1K	0.12%	236
2017 Q4	$275K	Buy	+910	New	+$253K	0.21%	145

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Claraphi Advisory Network's TXMD Position: Q4 2018 in Review

Claraphi Advisory Network sold out of TherapeuticsMD (TXMD) in Q4 2018, closing a stake of 510 shares — an estimated $167K sold.

Claraphi Advisory Network first reported a position in TXMD in Q4 2017 and held it in 4 quarters. The position peaked at $275K in Q4 2017. 140 funds tracked by Wall St. Rank hold TXMD as of Q4 2018.

Claraphi Advisory Network reported no remaining TherapeuticsMD position as of Q4 2018 after selling out during the quarter.
Claraphi Advisory Network sold 510 TherapeuticsMD shares in Q4 2018, an estimated $167K.
Claraphi Advisory Network first reported a position in TherapeuticsMD in Q4 2017 and held it in 4 quarters.
Claraphi Advisory Network's TherapeuticsMD position peaked at $275K in Q4 2017.
140 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2018.

Based on Claraphi Advisory Network's 13F filing for Q4 2018, filed 12 Feb 2019.